Topical treatment of atopic dermatitis in children: current challenges and answers
| Autor: | L. S. Namazova-Baranova, N. N. Murashkin, A. I. Materikin, E. T. Ambarchyan, R. V. Epishev |
|---|---|
| Jazyk: | English<br />Russian |
| Rok vydání: | 2017 |
| Předmět: | |
| Zdroj: | Vestnik Dermatologii i Venerologii, Vol 0, Iss 4, Pp 59-67 (2017) |
| Druh dokumentu: | article |
| ISSN: | 0042-4609 2313-6294 |
| DOI: | 10.25208/0042-4609-2016-0-4-72-85 |
| Popis: | Atopic dermatitis (AD) is the most prevalent skin disease in the early childhood and is a considerable problem both for patients and members of their families and for the society on the whole. In most cases, AD requires a long-term therapy such as the use of anti-inflammatory drugs. Selective inhibitors of the synthesis and release of proinflammatory cytokines - topical calcineurin inhibitors (Tcis) - are now used to solve this problem, with pimecrolimus being one of them. Pimecrolimus has been thoroughly examined for the past decade in different clinical studies involving a total of over 4,000 infants (below 2 years of age). These studies demonstrated the efficacy and safety of pimecrolimus for AD in children provided it is used in a long-term therapy on an intermittent basis. Unlike topical corticosteroids, the long-term use of pimecrolimus is not associated with any risk of development of systemic immunosuppression, skin atrophy, skin barrier dysfunction or systemic absorption so it is safe even if applied to the most sensitive skin areas. In view of this, the authors make a conclusion that pimecrolimus used in the form of a cream is a safe and efficient drug for the treatment of infants aged over three months suffering from atopic dermatitis. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|